Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Ahead of the release of October's consumer inflation data Tuesday, you may notice changes from the Bureau of Labor Statistics. When it comes to how it estimates health insurance costs, the move is expected to give a boost to the U.S. inflation measure which will reverse a trend that has provided some relief.
A handful of retailers will report earnings this week, including Home Depot, Target, Walmart and Macy's, as gas prices peaked in September to the end of this latest quarter while borrowing costs remain at their highest levels in decades.
The largest South American airline altered its travel policy because Taylor Swift was supposed to perform in Argentina's capital on Friday but moved the date to Sunday because of inclement weather.
